Navigation Links
TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
Date:10/17/2007

BOSTON, Oct. 17 /PRNewswire/ -- TEI Biosciences Inc. announces the launch of its SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction product. TEI has received 510(k) clearance from the U.S. Food and Drug Administration to market SurgiMend for expanded use in plastic and reconstructive surgery, including breast reconstruction, and for tendon augmentation, in addition to the previously cleared hernia repair and muscle flap reinforcement indications.

"SurgiMend has been the biologic material of choice for many general, plastic, and trauma surgeons for their hernia repair and muscle flap reinforcement needs. With multiple indications, excellent handling and suturing characteristics, and a rapid hydration rate that saves valuable operating room time, SurgiMend has the potential to become the medical community's primary choice for soft tissue repair and reconstruction. In addition, SurgiMend provides an opportunity for hospitals to cover a broad range of applications with a single biologic device at a single price point," said Yiannis Monovoukas, Ph.D., TEI's Chairman, President, and CEO.

SurgiMend is an acellular, terminally sterilized biologic matrix derived from the dermis of fetal calves, one of the purest sources of collagen available. It is intrinsically strong yet soft and pliable when hydrated, and handles like natural tissue; it readily conforms to the surgical site and is easily sutured. SurgiMend is rich in Type III collagen, the active collagen found in developing and healing tissues. It is not artificially crosslinked and its biochemistry and microporosity facilitate rapid cell penetration, revascularization, and integration with host tissues. SurgiMend is available in multiple sizes, both large and small, and can be stored dry at room temperature for up to three years.

SurgiMend will be on display at the American Society of Plastic Surgeons meeting in Baltimore, MD, October 29-30, at booth # 145.

About TEI Biosciences

A Boston-based, privately-held, leading biomedical company, TEI Biosciences Inc. (http://www.teibio.com) has applied its expertise in regenerative medicine to develop and commercialize novel biologic products for a broad spectrum of soft tissue repair and reinforcement applications -- from dura, tendon, and hernia repair to wound management and plastic and reconstructive surgery.

TEI sells its products directly and through partnerships with some of the world's major medical device companies. In addition to SurgiMend, TEI's marketed products include:

PriMatrix(TM) for skin wound management;

Durepair(R) for cranial and spinal dura mater repair;

Xenform(TM) for pelvic floor reconstruction; and

TissueMend(R) for tendon augmentation.

For further information, please contact:

Yiannis Monovoukas, Ph.D.

ymonovoukas@teibio.com

or

Tony Russo, Ph.D.

Russo Partners, LLC

(212) 845-4251

tony.russo@russopartnersllc.com.


'/>"/>
SOURCE TEI Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... ... , ... It wasn’t just the San Diego temps that soared this summer. ... has had a record-breaking number of guests for corporate cooking challenges, team events and ... company outings, family get-togethers, anniversaries and milestone birthdays. While all groups gathered in ...
(Date:9/12/2017)... ... 2017 , ... September 15, 2017. Pittsburgh, PA. The ... the Department of Surgery and Cancer and Director of the MRC-NIHR National Phenome ... His presentation, “Analytical Science in Precision Medicine: Facing the Challenges of the 21st ...
(Date:9/12/2017)... ... 2017 , ... Facet Life Sciences, a leading provider of development solutions (software ... PhD has joined the company’s Board of Directors. , Dr. Massa brings 38 ... Most recently he served as VP and Head of Global Regulatory Operations at Sanofi. ...
(Date:9/12/2017)... ... September 11, 2017 , ... As part of BD’s ... BD is sponsoring an educational webinar in recognition of World Sepsis Day ... estimated five million deaths annually, is preventable and treatable through increased awareness and ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):